pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
Fierce Biotech·21h ago·1 min read
save

Icon partners with Anthropic to integrate Claude AI into clinical trial planning

Aug 4, 2026·read at Fierce Biotech ↗DealPositive

Icon, a contract research organization, announced a multi-year collaboration with Anthropic to bring the Claude AI system into its clinical trial operations.

The partnership will combine Anthropic’s Life Sciences research team with Icon’s AI platform, Orbis, to enhance tools such as OneSearch and OnePlan, aiming to improve site selection, feasibility assessments, and real-time enrollment risk detection.

Anthropic’s regional head noted that operational bottlenecks like enrollment delays affect up to 80% of trials, and the combined expertise is intended to speed medicine delivery.

The collaboration also plans to embed Claude across Icon’s organization, including a Claude Code offering for development, allowing clients to tap into Icon’s trial insights through the AI.

source

This writeup was produced by pharmadog from original reporting by Fierce Biotech.

Original headline: “Icon inks Anthropic partnership to deploy Claude into clinical trials”

read at Fierce Biotech ↗
431 words · retrieved 13h ago
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
BRISTOLBRISTOL MYERS SQUIBBBRISTOL MYERS SQUIBB CONOVARTIS
topics
CRO/CDMO5

related stories

  • 20h agoSupernus, Indivior merger expected to result in ‘natural redundancies’BioSpace
  • 6h ago4 potential biotech M&A targets, plus a pretty sure bet from J&JBioSpace
  • 2d agoEditor’s Corner: Why an AstraZeneca-Bristol Myers Squibb merger is a bad ideaFierce Biotech
  • 4d agoTrump administration tries again to institute rebates in 340BBioPharma Dive
  • 4d agoModerna maintains 10% growth target despite Phase 3 norovirus missBioSpace